Guoyuan International issued a research report on Essex Bio-Technology on 1 April 2026. Essex posted steady operating performance growth in 2025 and kicked off its international expansion, as the Phase…
– Multiple Regulatory Approvals and Strategic Collaborations Strengthened Market Position Key Results Highlights: – Revenue Growth: 8.6% increase to approximately HK$1,813.8 million – Net Profit Increase: 3.5% rise to HK$318.1…
Essex Bio-Technology Limited (EssexBio or the Company; HKG: 1061) today announces its successful participation in the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO 2026), held from 5 to 8 February…
Essex Bio-Technology Limited (Essex or the Group, HKG: 1061) is pleased to announce that a Biologics License Application (BLA) for EB12-20145P (HLX04-O), a recombinant anti-VEGF humanized monoclonal antibody injection, has…
Essex Bio-Technology Ltd. (Essex or the Group, HKG: 1061) is pleased to announce that its wholly-owned subsidiary, Majeton Pte. Ltd. (Majeton), has entered into an exclusive Distribution Agreement with Osteopore…
Essex Bio-Technology Ltd. (Essex or the Group, HKG: 1061) is pleased to announce that its wholly-owned subsidiary, Essex Medipharma (Zhuhai) Co., Ltd. (Essex Medipharma), has entered into an Agency Agreement…
Essex Bio-Technology Limited (the Company, together with its subsidiaries, the Group) wishes to announce that Essex Bio-Investment Limited (Essex Bio-Investment), a wholly-owned subsidiary of the Group has on 13 October…
Essex Bio-Technology Ltd (EssexBio or the Group, Stock Code: HKG:1061) is pleased and honoured to announce that it is included in “Forbes Asia’s 200 Best Under A Billion 2022” –…
